Reply to H.J.A. Adams et al

J Clin Oncol. 2019 Apr 1;37(10):853-854. doi: 10.1200/JCO.18.02297. Epub 2019 Feb 11.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Brentuximab Vedotin
  • Cost-Benefit Analysis
  • Hodgkin Disease*
  • Humans
  • Positron-Emission Tomography

Substances

  • Brentuximab Vedotin